EcoDrugPlus


Trade Names	OPTIMARK OPTIMARK IN PLASTIC CONTAINER
Synonyms	Gadoversetamide MP-1177 Optimark
Status
Molecule Category	UNKNOWN
ATC	V08CA06
UNII	RLM74T3Z9D

Trade Names

OPTIMARK

OPTIMARK IN PLASTIC CONTAINER

Synonyms

Gadoversetamide

MP-1177

Optimark

Status

Molecule Category

UNKNOWN

ATC

V08CA06

UNII

RLM74T3Z9D


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Property Name	Value
Molecular Formula	C20H34GdN5O10
Molecular Weight	661.77
AlogP	None
Hydrogen Bond Acceptor	None
Hydrogen Bond Donor	None
Number of Rotational Bond	None
Polar Surface Area	None
Molecular species	None
Aromatic Rings	None
Heavy Atoms	None

Property Name

Value

Molecular Formula

C20H34GdN5O10

Molecular Weight

661.77

AlogP

None

Hydrogen Bond Acceptor

None

Hydrogen Bond Donor

None

Number of Rotational Bond

None

Polar Surface Area

None

Molecular species

None

Aromatic Rings

None

Heavy Atoms

None

Mechanism of Action	Action	Reference
Diagnostic agent	None	FDA

Mechanism of Action

Action

Reference

Diagnostic agent

None

FDA

Resources	Reference
ChEMBL	CHEMBL1200457
FDA SRS	RLM74T3Z9D
PubChem	444013

Resources

Reference

ChEMBL

CHEMBL1200457

FDA SRS

RLM74T3Z9D

PubChem

444013


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

GADOVERSETAMIDE

Physicochemical Descriptors

Bioactivity

Cross References